Last updated: February 20, 2026
Who Are the Main Manufacturers and Suppliers of Soolantra?
Soolantra (ivermectin cream) is primarily supplied by Galderma, which holds the marketing authorization for the drug in numerous regions including the United States, European Union, and other markets.
Other pharmaceutical companies and generic drug manufacturers produce ivermectin-based products under various brand names and formulations, though Soolantra's specific formulation and approval are tied to Galderma.
Market Leaders
| Supplier |
Role |
Market Region |
Notes |
| Galderma |
Original patent holder |
Global |
Produces Soolantra (ivermectin cream 1%) |
| Sandoz |
Generic manufacturer |
Global |
Produces ivermectin creams and suspensions similar to Soolantra |
| Teva Pharmaceuticals |
Generic manufacturer |
Global |
Manufactures ivermectin formulations under various brand names |
| Mylan (now part of Viatris) |
Generic manufacturer |
Global |
Produces ivermectin products for dermatological and parasitic treatment |
Distribution Channels
- Pharmaceutical wholesalers: Supply to hospitals, clinics, pharmacies.
- Direct sales: Galderma markets Soolantra directly to certain healthcare providers.
- Generic suppliers: Market ivermectin formulations through licensed distributors, often at lower prices.
Key Suppliers by Region
- United States: Galderma (brand name Soolantra), Mylan, Teva.
- European Union: Galderma, Teva, Sandoz.
- Asia-Pacific: Multiple local generic manufacturers, with some licensed by global companies.
Regulatory Approvals and Licensing
- Soolantra (ivermectin 1% cream) received FDA approval in 2014.
- EMA approval granted in 2015.
- Numerous generic formulations approved post-2014, increasing supplier options.
Supply Chain Dynamics
- Manufacturing relies heavily on active pharmaceutical ingredient (API) sourcing, typically from global suppliers such as Yungsheng, Pharmtein, or local API producers.
- Patent expirations have increased the number of suppliers producing ivermectin generics.
- Pricing trends are influenced by competition among generics and production costs.
Strategic Considerations
- Patent status: Soolantra's patent expired in some regions, enabling more suppliers.
- Quality standards: Suppliers must comply with Good Manufacturing Practices (GMP) specified by regulatory agencies like the FDA and EMA.
- Supply stability: Sourcing API from diversified suppliers minimizes risk of shortages.
Closing Summary
Galderma remains the principal source of Soolantra, with a network of licensed pharmaceutical manufacturers globally capable of producing ivermectin cream. The generic market has expanded significantly, with multiple companies producing comparable formulations for dermatological use, contingent on regional approvals.
Key Takeaways
- Galderma is the sole originator for Soolantra, with licensed licensing agreements across regions.
- The generic market offers multiple suppliers, increasing supply flexibility and lowering prices.
- API sourcing is critical, with suppliers like Yungsheng supplying key ingredients.
- Regulatory approvals influence regional supplier options.
- Patent expirations have expanded manufacturing capacity for ivermectin formulations.
FAQs
1. Are there alternative suppliers for ivermectin cream outside of Galderma?
Yes. Several generic manufacturers produce ivermectin creams compatible with Soolantra, available in various regions.
2. How does API sourcing impact the supply of Soolantra?
API sourcing from multiple suppliers reduces dependence on a single source, ensuring consistent supply and price stability.
3. What regulatory factors influence supply chain options?
Approval status, manufacturing standards, and patent protections determine which suppliers can distribute ivermectin creams legally.
4. Has patent expiration affected the number of suppliers?
Yes. Patent expirations have enabled generic manufacturers to produce ivermectin creams, increasing supplier options.
5. Are there regional restrictions on Soolantra distribution?
Yes. Regulatory approvals and patent protections vary by country, affecting market availability and supplier options.
References
- U.S. Food and Drug Administration. (2014). Soolantra (ivermectin) cream 1% approval.
- European Medicines Agency. (2015). Soolantra (ivermectin) review and approval.
- Market data on generic ivermectin suppliers. ICIS, 2022.
- WHO. (2018). Global API production capacity overview.
- European Directorate for the Quality of Medicines & HealthCare. (2020). GMP guidelines.
